Zobrazeno 71 - 80
of 89
pro vyhledávání: '"Stefan Hantel"'
Autor:
Sabine Pinnetti, E. Seewaldt-Becker, Eleuterio Ferrannini, Leo Seman, Hans-Juergen Woerle, Stefan Hantel
Aim This Phase IIb, randomized, double-blind, placebo-controlled trial evaluated the efficacy, safety, tolerability and pharmacokinetics of empagliflozin in patients with type 2 diabetes. Methods Four hundred and eight patients (treatment-naive or af
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::628355accc5d6f217b55b6412504af91
http://hdl.handle.net/11568/506135
http://hdl.handle.net/11568/506135
Autor:
E. Seewaldt-Becker, Hans-Juergen Woerle, Stefan Hantel, Sreeraj Macha, Leo Seman, Sabine Pinnetti, Tim Heise
Publikováno v:
Diabetes, obesitymetabolism. 15(7)
Aim To investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of empagliflozin in patients with type 2 diabetes following oral administration of 10, 25 or 100 mg doses once daily over 28 days. Methods A total of 78 patients were
Autor:
Martin Feuring, Joseph A. Caprini, Andreas Clemens, Bengt I. Eriksson, Stefan Hantel, John J. Smith, Janet Schnee, Gregory W. Barsness
Publikováno v:
Thrombosis research. 130(3)
Introduction Several anticoagulants have been associated with a ‘rebound effect’ that potentially increases the risk of thrombosis and cardiovascular events following discontinuation. Four Phase 3 trials of dabigatran etexilate in major orthopedi
Autor:
Samuel Z. Goldhaber, Sam Schulman, Jörg Kreuzer, Martin Feuring, Sebastian Schellong, Ajay K. Kakkar, Stefan Hantel, Henry Eriksson
Publikováno v:
Blood. 126:4730-4730
Introduction: In the RE-COVER®/RE-COVER II™ global randomized trials investigating the treatment of acute venous thromboembolism (VTE), efficacy and safety outcomes of dabigatran etexilate (dabigatran) versus warfarin were compared. This sub-analy
Autor:
Uli C. Broedl, Erich Bluhmki, Stefan Hantel, John M. Lachin, Hans-Juergen Woerle, Silvio E. Inzucchi, Roberto Ferrari, Christoph Wanner, O.E. Johansen, Bernard Zinman
Publikováno v:
Canadian Journal of Diabetes. 37:S29-S30
Autor:
Jeffrey S, Ginsberg, Bruce L, Davidson, Philip C, Comp, Charles W, Francis, Richard J, Friedman, Michael H, Huo, Jay R, Lieberman, James E, Muntz, Gary E, Raskob, Mary L, Clements, Stefan, Hantel, Janet M, Schnee, Joseph A, Caprini
Publikováno v:
The Journal of arthroplasty. 24(1)
Dabigatran, an oral once-daily unmonitored thrombin inhibitor, has been tested elsewhere using enoxaparin 40 mg once daily. We used the North American enoxaparin 30 mg BID regimen as the comparator. This was a double-blind, centrally randomized trial
Autor:
Sebastian Schellong, Henry Eriksson, Joerg Kreuzer, Sam Schulman, Ajay K. Kakkar, Samuel Z. Goldhaber, Martin Feuring, Stefan Hantel, Clive Kearon, Patrick Mismetti
Publikováno v:
Blood. 124:4270-4270
[Graphic][1] Background: The double-blind, parallel-group, noninferiorityRE-MEDY™ study comparing the direct oral thrombin inhibitor dabigatran etexilate to warfarin in the prevention of secondary venous thromboembolism (VTE) showed non-inferiority
Autor:
Sam Schulman, Henry Eriksson, Ajay Kakkar, Clive Kearon, Sebastian M Schellong, Patrick Mismetti, Martin Feuring, Stefan Hantel, Joerg Kreuzer, Samuel Z. Goldhaber
Publikováno v:
Blood. 124:594-594
Background: In the RE-COVER™ and RE-COVER™ II trials, dabigatran etexilate (DE) was as effective as warfarin (W) for prevention of recurrent venous thromboembolism (VTE) in patients with acute VTE, and was associated with a lower risk of bleeding
Autor:
Thomas Hach, Uli C. Broedl, John E. Gerich, Hans-Juergen Woerle, B. Gibelin, G. Kim, Afshin Salsali, Stefan Hantel
Publikováno v:
Diabetes & Metabolism. 40:A97
Introduction Nous avons analyse les donnees groupees de quatre etudes de phase III randomisees controlees par placebo concernant 2 477 patients DT2 (55,6 ans ± 10,2 ; HbA1c 7,99 % ± 0,8 ;IMC 28,7 kg/m 2 ± 5,5) recevant empagliflozine (EMPA) 10 mg
Autor:
John E. Gerich, G. Kim, Stefan Hantel, Afshin Salsali, Hans-Juergen Woerle, Uli C. Broedl, Thomas Hach, B. Gibelin
Publikováno v:
Diabetes & Metabolism. 40:A97
Introduction Les inhibiteurs du SGLT2 augmentent la glycosurie. Cela favorise- t-il les Infections Urinaires et les Infections Genitales ? Quatre etudes (Phase III) randomisees controlees vs placebo ont evalue chez des DT2 l’effet de 24 semaines d